IRIS
CRISCUOLO, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 545
AS - Asia 442
NA - Nord America 361
SA - Sud America 72
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 1.435
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 356
IT - Italia 200
SE - Svezia 188
SG - Singapore 151
CN - Cina 147
HK - Hong Kong 124
BR - Brasile 65
DE - Germania 51
RU - Federazione Russa 49
FI - Finlandia 26
IE - Irlanda 9
AT - Austria 5
UZ - Uzbekistan 5
IN - India 4
NL - Olanda 4
ZA - Sudafrica 4
AR - Argentina 3
AU - Australia 3
CM - Camerun 3
LT - Lituania 3
PH - Filippine 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BE - Belgio 2
CA - Canada 2
EC - Ecuador 2
GB - Regno Unito 2
MX - Messico 2
PL - Polonia 2
TR - Turchia 2
VN - Vietnam 2
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
FR - Francia 1
JO - Giordania 1
KR - Corea 1
MA - Marocco 1
NI - Nicaragua 1
RO - Romania 1
UA - Ucraina 1
UY - Uruguay 1
Totale 1.435
Salva come PNG Salva come JPEG
Città #
Hong Kong 122
Milan 106
Shanghai 87
Ashburn 78
Singapore 65
Princeton 39
Lawrence 38
New York 26
Helsinki 24
Brescia 21
Rome 21
Moscow 19
Falkenstein 15
Cesano Boscone 11
Nuremberg 11
Dublin 9
The Dalles 8
Guangzhou 7
Boardman 5
Council Bluffs 5
Los Angeles 5
Turin 5
Washington 5
Ancona 4
Frankfurt am Main 4
Pune 4
Santa Clara 4
Shenzhen 4
South San Francisco 4
Tashkent 4
Vienna 4
Beijing 3
Bergamo 3
Bologna 3
Busto Arsizio 3
Magnago 3
Melbourne 3
São Paulo 3
Xi'an 3
Belo Horizonte 2
Brasília 2
Brussels 2
Como 2
Dallas 2
Gatchina 2
Hangzhou 2
Ho Chi Minh City 2
Kassel 2
Kunming 2
Kwai Chung 2
Las Vegas 2
London 2
Manaus 2
Munich 2
Seattle 2
Segrate 2
Seregno 2
Shijiazhuang 2
Abu Dhabi 1
Amman 1
Angra dos Reis 1
Araras 1
Bacoor 1
Balneário Camboriú 1
Bari 1
Barra Mansa 1
Barra do Piraí 1
Barreiras 1
Barretos 1
Batangas 1
Bauru 1
Betim 1
Bloemfontein 1
Borås 1
Caicó 1
Cairo 1
Camaçari 1
Campos dos Goytacazes 1
Cape Town 1
Caruaru 1
Caxias do Sul 1
Chacabuco 1
Changsha 1
Changzhi 1
Changzhou 1
Chone 1
Chongqing 1
Diadema 1
Diamantina 1
Dongyang 1
Dubai 1
Espoo 1
Ferraz de Vasconcelos 1
Foshan 1
Guarulhos 1
Guayaquil 1
Hefei 1
Houston 1
Ibirité 1
Indaiatuba 1
Totale 868
Salva come PNG Salva come JPEG
Nome #
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects 53
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy 52
The interferon landscape along the respiratory tract impacts the severity of COVID-19 50
Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19 50
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models 48
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine 46
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs 43
A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation 42
Alternative methods of vaccine delivery: An overview of edible and intradermal vaccines 42
Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection 40
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials 40
Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge 37
Bacteriophages and Their Immunological Applications against Infectious Threats 37
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 37
Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects 37
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection 35
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II 34
Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021 33
Characterization of two human monoclonal anti-E2/HCV antibodies for potential application in prevention and treatment of HCV infection 31
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 31
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? 31
IN VIVO PROTECTION CONFERRED BY HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST HSV-1 AND 2 31
Evaluation of synergistic interactions of anti-HCV/E2 monoclonal antibodies 31
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases 30
HUMAN MONOCLONAL ANTIBODY ENDOWED WITH ANTI-HSV-1 AND -2 ACTIVITY STRONGLY INHIBITS VIRUS REPLICATION 30
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion? 30
Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols 30
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes 30
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects 30
Viral Respiratory Pathogens and Lung Injury 29
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. 28
The initial interplay between HIV and mucosal innate immunity 27
Broadly neutralizing human monoclonal antibodies: a novel resource against influenza viruses 27
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2 26
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines 26
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro 26
Synergistic neutralization of HCV by two broadly neutralizing human monoclonal antibodies 26
Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis 25
Role and potential therapeutic use of antibodies against herpetic infections 24
A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells 23
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome 23
Characterization of a lineage c.36 sars-cov-2 isolate with reduced susceptibility to neutralization circulating in lombardy, italy 23
Molecular characterization of the human neutralizing response against hepatitis C virus and its role in the prediction of the infection outcome 23
Next Generation Vaccines for Infectious Diseases 22
Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity 22
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle 21
Editorial: Viral escape of mucosal immunity in sexually transmitted diseases 20
Single spike mutation differentiating XBB.1 and XBB.1.5 enhances SARS-CoV-2 cell-to-cell transmission and facilitates serum-mediated enhancement 20
Phage Therapy: An Alternative to Antibiotics 20
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19 19
null 1
Totale 1.592
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/202113 2 0 0 2 4 0 2 0 0 3 0 0
2021/202284 6 3 10 10 13 7 9 2 2 9 0 13
2022/2023356 89 78 49 7 3 41 33 30 15 2 8 1
2023/2024315 1 20 42 62 19 62 9 25 13 8 18 36
2024/2025769 81 20 13 35 33 94 158 170 90 63 12 0
Totale 1.592